Bayesian Capital Management’s Everbridge, Inc. Common Stock EVBG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-18,360
Closed -$639K 1172
2024
Q1
$639K Buy
+18,360
New +$517K 0.06% 385
2023
Q2
Sell
-20,958
Closed -$727K 1127
2023
Q1
$727K Buy
20,958
+13,700
+189% +$438K 0.09% 300
2022
Q4
$215K Buy
+7,258
New +$223K 0.03% 576
2021
Q3
Sell
-1,814
Closed -$247K 588
2021
Q2
$247K Buy
+1,814
New +$227K 0.06% 328
2020
Q4
Sell
-5,427
Closed -$682K 699
2020
Q3
$682K Sell
5,427
-1,214
-18% -$165K 0.17% 162
2020
Q2
$919K Sell
6,641
-1,085
-14% -$141K 0.2% 140
2020
Q1
$822K Buy
7,726
+3,697
+92% +$363K 0.18% 166
2019
Q4
$315K Buy
+4,029
New +$311K 0.05% 416
2018
Q4
Sell
-4,875
Closed -$281K 826
2018
Q3
$281K Sell
4,875
-1,231
-20% -$66.4K 0.05% 481
2018
Q2
$290K Buy
+6,106
New +$260K 0.07% 414
2018
Q1
Sell
-11,600
Closed -$345K 865
2017
Q4
$345K Buy
+11,600
New +$316K 0.07% 389

Other funds holding EVBG

Bayesian Capital Management's EVBG Position: Q2 2024 in Review

Bayesian Capital Management sold out of Everbridge, Inc. Common Stock (EVBG) in Q2 2024, closing a stake of 18,360 shares — an estimated $639K sold.

Bayesian Capital Management first reported a position in EVBG in Q4 2017 and held it in 11 quarters. The position peaked at $919K in Q2 2020. 154 funds tracked by Wall St. Rank hold EVBG as of Q2 2024.

  • Bayesian Capital Management reported no remaining Everbridge, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 18,360 Everbridge, Inc. Common Stock shares in Q2 2024, an estimated $639K.
  • Bayesian Capital Management first reported a position in Everbridge, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
  • Bayesian Capital Management's Everbridge, Inc. Common Stock position peaked at $919K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Everbridge, Inc. Common Stock as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.